Phillips-Medisize Partners with InterSystems in Connected Health Platform

InterSystemsPhillips-Medisize, a Molex company, has joined forces with InterSystems, a global leader in healthcare software technology to develop the third-generation Connected Health Platform. The integration of InterSystems HealthShare offers an information-sharing and analytics platform foundation designed for connected drug delivery devices, bio sensors and regulated Mobile Medical Applications (SaMD/MMA).

"Our collaboration with InterSystems brings together the information that matters - connecting pharmaceutical companies, providers, patients, and payers on the Phillips-Medisize Connected Health Platform through a unified healthcare medication record and powerful analytics that span the care continuum," said Matt Jennings, CEO and President, Phillips-Medisize.

An estimated 50 percent of medications for chronic diseases are not taken as prescribed. A 2017 Annals of Internal Medicine review reports that an estimated 125,000 deaths and 10 percent of U.S. hospitalizations are linked to patient non-adherence to prescribed medications, which results in over $290 billion dollars to U.S. healthcare annually.

Phillips-Medisize was the first company to develop an FDA-approved combination Connected Medicine solution to support patients and develop a deeper understanding of how they take their medication. They have applied this experience to the development of their 3rd Generation Platform, built on InterSystems HealthShare, for the pharmaceutical delivery environment. The platform will enable pharmaceutical companies to connect medication and diagnostic information across their drugs and therapy areas on a single, unified platform at an exceptional scale.

Data collected by connected devices using the Phillips-Medisize Connected Health Platform can be shared securely to inform the patient and their healthcare provider when medications have been administered and can be combined with data from diagnostic devices and biometric sensors to generate further insights. Pharmaceutical companies working with Phillips-Medisize will receive an exclusive, secure private cloud.

"Poor medication adherence currently yields unnecessary human suffering and significantly reduced patient health around the world. The collaboration between InterSystems and Phillips-Medisize aims to change that paradigm with a highly scalable platform to securely connect and aggregate data from rare diseases to many millions of patients across global geographies; encouraging patients in the most effective use of prescribed medications to improve outcomes," adds Don Woodlock, head of the HealthShare business unit at InterSystems.

About Phillips-Medisize

Phillips-Medisize, LLC, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize's core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions.

About InterSystems

InterSystems is the engine behind the world's most important applications. In healthcare, finance, government, and other sectors where lives and livelihoods are at stake, InterSystems is the power behind what mattersTM. Founded in 1978, InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...